PST2286 is primarily investigated for its potential in neurodegenerative disease research, particularly targeting conditions associated with protein misfolding and aggregation. It has shown promise in modulating cellular pathways involved in neuronal protection and reducing toxic protein buildup, such as tau or amyloid species, in preclinical models. Its application extends to studies on cognitive decline, where it demonstrates the ability to improve synaptic function and memory retention in animal models of Alzheimer’s disease. Due to its blood-brain barrier permeability and favorable pharmacokinetic profile, PST2286 is considered a candidate for oral therapeutic development in early-stage neurodegeneration. Current use remains restricted to laboratory and clinical trial settings, focusing on safety, dosing, and biomarker response evaluation.